Receptor tyrosine kinase inhibitors block proliferation of TGEV mainly through p38 mitogen-activated protein kinase pathways

Emerging coronaviruses (CoVs) primarily cause severe gastroenteric or respiratory diseases in humans and animals, and no approved therapeutics are currently available. Here, A9, a receptor tyrosine kinase inhibitor (RTKI) of the tyrphostin class, is identified as a robust inhibitor of transmissible...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Wanyu, Xie, Wenting, Liu, Yunbo, Sui, Baokun, Zhang, Hao, Liu, Liran, Tan, Yubei, Tong, Xiaohan, Fu, Zhen F., Yin, Ping, Fang, Liurong, Peng, Guiqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114126/
https://www.ncbi.nlm.nih.gov/pubmed/31751591
http://dx.doi.org/10.1016/j.antiviral.2019.104651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114126/
https://www.ncbi.nlm.nih.gov/pubmed/31751591
http://dx.doi.org/10.1016/j.antiviral.2019.104651

Ejemplares similares